ATE442857T1 - Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird) - Google Patents

Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)

Info

Publication number
ATE442857T1
ATE442857T1 AT04743211T AT04743211T ATE442857T1 AT E442857 T1 ATE442857 T1 AT E442857T1 AT 04743211 T AT04743211 T AT 04743211T AT 04743211 T AT04743211 T AT 04743211T AT E442857 T1 ATE442857 T1 AT E442857T1
Authority
AT
Austria
Prior art keywords
cynos
cird
vaccine composition
respiratory disease
vaccination
Prior art date
Application number
AT04743211T
Other languages
German (de)
English (en)
Inventor
John Brownlie
Victoria Jane Chalker
Kerstin Erles
Original Assignee
Royal Veterinary College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Royal Veterinary College filed Critical Royal Veterinary College
Application granted granted Critical
Publication of ATE442857T1 publication Critical patent/ATE442857T1/de

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/118Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/0241Mollicutes, e.g. Mycoplasma, Erysipelothrix
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/295Assays involving biological materials from specific organisms or of a specific nature from bacteria from Chlamydiales (o)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/30Assays involving biological materials from specific organisms or of a specific nature from bacteria from Mycoplasmatales, e.g. Pleuropneumonia-like organisms [PPLO]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/315Assays involving biological materials from specific organisms or of a specific nature from bacteria from Streptococcus (G), e.g. Enterococci
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/12Pulmonary diseases

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04743211T 2003-07-01 2004-07-01 Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird) ATE442857T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0315323.6A GB0315323D0 (en) 2003-07-01 2003-07-01 Vaccine composition
PCT/GB2004/002865 WO2005002618A1 (fr) 2003-07-01 2004-07-01 Composition vaccinale pour vacciner des chiens contre les maladies respiratoires infectieuses canines (cird)

Publications (1)

Publication Number Publication Date
ATE442857T1 true ATE442857T1 (de) 2009-10-15

Family

ID=27676393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04743211T ATE442857T1 (de) 2003-07-01 2004-07-01 Vakzine zusammensetzung zur impfung von hunden gegen infektiöse atemwegserkrankung bei hunden (cird)

Country Status (20)

Country Link
US (3) US8329194B2 (fr)
EP (2) EP1638599B1 (fr)
JP (1) JP5698890B2 (fr)
KR (1) KR20060106809A (fr)
CN (1) CN1845754A (fr)
AT (1) ATE442857T1 (fr)
AU (1) AU2004253344B2 (fr)
BR (1) BRPI0412194A (fr)
CA (1) CA2530797C (fr)
DE (1) DE602004023196D1 (fr)
DK (1) DK2050463T3 (fr)
ES (2) ES2356396T3 (fr)
GB (1) GB0315323D0 (fr)
MX (1) MXPA06000278A (fr)
NO (1) NO20056207L (fr)
NZ (1) NZ544453A (fr)
PT (1) PT2050463E (fr)
RU (1) RU2006102863A (fr)
WO (1) WO2005002618A1 (fr)
ZA (1) ZA200600918B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11865172B2 (en) 2005-04-21 2024-01-09 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7682619B2 (en) 2006-04-06 2010-03-23 Cornell Research Foundation, Inc. Canine influenza virus
CN100388952C (zh) * 2006-04-25 2008-05-21 范红结 一种链球菌重组亚单位疫苗及其制备方法
KR101192127B1 (ko) * 2006-11-03 2012-10-17 쉐링-프라우 리미티드 개 라임병 백신
AU2011224507A1 (en) * 2010-03-10 2012-08-30 Intervet International B.V. Method for protecting against disease caused by secondary pathogens
LT2670432T (lt) 2011-02-04 2021-05-25 Zoetis Services Llc Imunogeninės bordetalla bronchiseptica kompozicijos
WO2012104820A1 (fr) * 2011-02-04 2012-08-09 Pfizer Inc. Compositions pour traiter un complexe de maladies respiratoires canines
MX363510B (es) 2012-05-31 2019-03-26 Zoetis Llc Vacuna con coronavirus respiratorio canino para proteccion contra infecciones de b. bronchiseptica.
CN111499702B (zh) * 2020-05-07 2021-04-06 山东畜牧兽医职业学院 一种马链球菌兽疫亚种的检测试剂盒及检测方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4567043A (en) * 1983-06-15 1986-01-28 American Home Products Corporation (Del.) Canine corona virus vaccine
US4567042A (en) * 1983-06-15 1986-01-28 American Home Products Corporation Inactivated canine coronavirus vaccine
GB8426468D0 (en) 1984-10-19 1984-11-28 Technology Licence Co Ltd Monoclonal antibodies
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
GB8517895D0 (en) * 1985-07-16 1985-08-21 Technology Licence Co Ltd Monoclonal antibodies
ATE71303T1 (de) 1986-01-14 1992-01-15 Nederlanden Staat Verfahren zur herstellung immunologischer komplexe und diese enthaltende pharmazeutische zusammensetzung.
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4944942A (en) * 1987-08-27 1990-07-31 Mobay Corporation Intranasal vaccination of horses with inactivated microorganisms or antigenic material
US4944972A (en) * 1987-12-31 1990-07-31 American National Can Company Coextrusion apparatus, methods, and related films and packages
US5672350A (en) * 1989-08-22 1997-09-30 Veterinary Infectious Disease Organization Recombinant bovine coronavirus E2 and E3 polypeptides and vaccines
US5178860A (en) * 1989-09-01 1993-01-12 Coopers Animal Health Limited Adjuvant complexes and vaccine made therefrom
GB8919819D0 (en) * 1989-09-01 1989-10-18 Coopers Animal Health Complexes having adjuvant activity
US5583014A (en) * 1990-07-03 1996-12-10 Bayer Corporation Preparation and use of enzyme-detergent extracted Streptococcus zoopidemicus vaccine
US6057436A (en) * 1990-11-14 2000-05-02 Pfizer Inc. Canine coronavirus S gene and uses therefor
US6372224B1 (en) * 1990-11-14 2002-04-16 Pfizer Inc. Canine coronavirus S gene and uses therefor
NZ240558A (en) * 1990-11-14 1994-11-25 Smithkline Beecham Corp Recombinant feline coronavirus s proteins useful in diagnosis and vaccination against feline peritonitis virus disease
ES2213743T3 (es) 1991-04-25 2004-09-01 Akzo Nobel N.V. Vacuna de subunidad de coronavirus canino.
DE4134297A1 (de) * 1991-10-17 1993-04-22 Behringwerke Ag Monoclonale antikoerper gegen mycoplasma pneumoniae, diese produzierende hybridome, verfahren zu deren herstellung sowie deren verwendung
EP0640098B1 (fr) 1992-05-08 2002-10-09 Pfizer Inc. Gene s du coronavirus canin et ses applications
US5750112A (en) * 1993-02-26 1998-05-12 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
DE69528450T2 (de) * 1994-02-18 2003-01-23 Solidose L L C Impfung von tieren mit getrockneten pelletierten biologischen materialien
ATE274579T1 (de) * 1995-06-12 2004-09-15 Univ Kansas State Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
US5753235A (en) * 1996-02-15 1998-05-19 Heska Corporation Recombinant canine herpesviruses
EP0934410A1 (fr) 1996-10-11 1999-08-11 Human Genome Sciences, Inc. Inhibiteur cerebro-associe de l'activateur du plasminogene de type tissulaire
US6080725A (en) * 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6682745B1 (en) * 1998-07-28 2004-01-27 Christiaan Antonius Arnoldus Jacobs Use of bacterium for manufacture of a vaccine
AU1408499A (en) 1997-11-14 1999-06-07 Thomas P. Brown Compositions and methods to prevent turkey enteritis
US6248329B1 (en) * 1998-06-01 2001-06-19 Ramaswamy Chandrashekar Parasitic helminth cuticlin nucleic acid molecules and uses thereof
DE60007668T2 (de) 1999-01-26 2004-12-02 Akzo Nobel N.V. Verwendung lebender abgeschwächter Bakterien zur Herstellung eines submukosalen Impstoffes
US20010048927A1 (en) * 2000-02-01 2001-12-06 Richard Stephens Porin B (PorB) as a therapeutic target for prevention and treatment of infection by chlamydia
US6548069B2 (en) * 2001-02-03 2003-04-15 Hmv Associates, Inc. Multivalent Mycoplasma bacterin
WO2003018051A1 (fr) * 2001-08-27 2003-03-06 Vic Jira Composition antifongique
GB0217434D0 (en) 2002-07-27 2002-09-04 Royal Vetinary College Biological material
DK1560594T3 (da) 2002-10-11 2010-10-04 Bengt Guss Antigeniske sammensætninger til immunisering af ikke-menneskelige pattedyr mod Streptococcus equi
US7793433B2 (en) * 2006-07-14 2010-09-14 Footbalance System Oy Individually formed footwear and a related method

Also Published As

Publication number Publication date
PT2050463E (pt) 2013-10-29
EP1638599B1 (fr) 2009-09-16
WO2005002618A1 (fr) 2005-01-13
RU2006102863A (ru) 2006-09-10
JP2007526884A (ja) 2007-09-20
EP1638599A1 (fr) 2006-03-29
US20110059128A1 (en) 2011-03-10
EP2050463A3 (fr) 2010-01-20
JP5698890B2 (ja) 2015-04-08
DE602004023196D1 (de) 2009-10-29
GB0315323D0 (en) 2003-08-06
EP2050463A2 (fr) 2009-04-22
BRPI0412194A (pt) 2006-08-22
AU2004253344A1 (en) 2005-01-13
ES2356396T3 (es) 2011-04-07
NZ544453A (en) 2009-04-30
US8329194B2 (en) 2012-12-11
DK2050463T3 (da) 2013-09-02
US20080220018A1 (en) 2008-09-11
NO20056207L (no) 2006-01-31
CA2530797C (fr) 2014-08-26
CN1845754A (zh) 2006-10-11
US20070098739A1 (en) 2007-05-03
MXPA06000278A (es) 2006-04-07
EP2050463B1 (fr) 2013-08-21
CA2530797A1 (fr) 2005-01-13
ZA200600918B (en) 2007-07-25
AU2004253344B2 (en) 2010-04-29
KR20060106809A (ko) 2006-10-12
ES2432175T3 (es) 2013-12-02

Similar Documents

Publication Publication Date Title
NO20056207L (no) Sammensetning for vaksinering av hunder
ATE461710T1 (de) Nipah-virus-impfstoffe
ATE451119T1 (de) Untereinheit-impfstoff gegen das respiratorische synzytialvirus
CY1120015T1 (el) Μεθοδοι χορηγησης εμβολιων
NO20015073D0 (no) Vaksiner
ATE309268T1 (de) Verfahren zur identifizierung, isolierung und herstellung von antigenen eines spezifischen pathogens
PA8549801A1 (es) Vacuna de mycoplasma bovis y metodos para reducir la neumonia en animales
AR047581A1 (es) Vacunas de calicivirus felino
DK1425038T4 (da) Svækkede bakterier, der er anvendelige i vacciner
DE50010240D1 (de) Impfstoff gegen infektionen mit lentiviren, wie dem felinen immunschwäche-virus der katze
HUP0401077A2 (hu) Mycoplasma bovis fertőzési modell, valamint eljárások M. bovis bejuttatására és tüdőgyulladásos tüdőléziók indukálására
ATE495758T1 (de) Virulentes systemisches felines calicivirus
Frank et al. The probability of severe disease in zoonotic and commensal infections
WO2004030614A3 (fr) Vaccins contenant des virus impliques dans le syndrome de la malabsorption aviaire et procedes d'administration correspondants
AR019785A1 (es) Pestivirus no diseminantes
DE60239753D1 (de) Impfstoff gegen infektiöses lachsanämievirus
AU2003294192A8 (en) Inclusion bodies as antigens for the oral vaccination of animals
WO2004043286A3 (fr) Utilisation de rmlt en tant qu'antigene marqueur pour vaccins et en tant qu'adjuvant synergetique avec amphigen
TH95334A (th) การใช้ของวัคซีนสำหรับการรักษา/การป้องกันของการแพร่เชื้อของจุลชีพก่อโรค
Henry Rabies in Asia: 2004
ATE540693T1 (de) Impfung und impfstoffe gegen hundeherpesvirus
TH95334B (th) การใช้ของวัคซีนสำหรับการรักษา/การป้องกันของการแพร่เชื้อของจุลชีพก่อโรค
TH150115A (th) วัคซีน ไมโคพลาสมา ไฮโอนิวโมนิเอ ที่มีชีวิต ชนิดไม่ร้ายแรง ที่มีแอดจูแวนท์
RU2002115519A (ru) Способ вакцинопрофилактики эпидемического паротита на крайнем севере
ES2172482B1 (es) Adicion de la patente es200100402 "vacuna para la proteccion de perros frente a la leishmania".

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties